{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:29:19Z","timestamp":1788348559698,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to identify best practices for treating 13q deletion syndrome (13q\u2212) patients with retinoblastoma in the era of super\u2010selective ophthalmic artery chemosurgery (OAC) and intravitreal injection therapy (IVIT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective study of 21 eyes from 14 patients with retinoblastoma and 13q\u2212 who were treated at Memorial Sloan Kettering Cancer Center (MSKCC) between May 2006 and May 2020, with a mean follow up of 3.7\u00a0years. Ocular survival, patient survival, and treatment toxicities were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine of the 12 eyes that underwent OAC\/IVIT at MSKCC have been progression free for at least 1\u00a0year since their last treatments. Fifteen out of 26 OAC cycles resulted in grade 3\u20104 hematologic toxicity. There was one death from sepsis in the setting of intravenous chemotherapy (IVC) for metastatic disease that occurred after OAC\/IVIT therapy. The 2\u2010year Kaplan\u2010Meier ocular survival estimate for the whole cohort was 75% and for the eyes that received OAC or IVIT at MSKCC 83%. For OAC hematologic toxicities, one platelet transfusion and two filgrastim doses were administered, and one patient was hospitalized for neutropenic fevers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The majority of 13q\u2212 eyes treated with OAC\/IVIT\u2010based regimens can be cured, and there were no deaths related to complications from OAC or IVIT. 13q\u2212 Patients did have increased risk of systemic treatment complications, even from super\u2010selective chemotherapies. Despite these toxicities, only one patient developed febrile neutropenia, one patient required a blood product transfusion, and two patients received filgrastim for both OAC and IVC complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Pr\u00e9cis<\/jats:title><jats:p>Children with 13q deletion syndrome with retinoblastoma managed with intra\u2010arterial and intravitreal chemotherapy have excellent patient and ocular survival with acceptable toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.28845","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T15:12:42Z","timestamp":1608822762000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retinoblastoma management in 13q deletion syndrome patients using super\u2010selective chemotherapies and other cancer\u2010directed interventions"],"prefix":"10.1002","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0539-8727","authenticated-orcid":false,"given":"Lucy V.","family":"Cobbs","sequence":"first","affiliation":[{"name":"Ophthalmic Oncology Service Department of Surgery Memorial Sloan Kettering Cancer Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[{"name":"Ophthalmic Oncology Service Department of Surgery Memorial Sloan Kettering Cancer Center  New York New York"},{"name":"Department of Ophthalmology Weill Cornell Medical College, New York Presbyterian Hospital  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8091-6067","authenticated-orcid":false,"given":"Ira J.","family":"Dunkel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York"},{"name":"Department of Pediatrics Weill Cornell Medical College New York Presbyterian Hospital  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Pierre","family":"Gobin","sequence":"additional","affiliation":[{"name":"Ophthalmic Oncology Service Department of Surgery Memorial Sloan Kettering Cancer Center  New York New York"},{"name":"Interventional Neuroradiology Department of Neurosurgery Weill Cornell Medicine New York Presbyterian Hospital  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Brodie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology NYU Langone Health  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Ophthalmic Oncology Service Department of Surgery Memorial Sloan Kettering Cancer Center  New York New York"},{"name":"Department of Ophthalmology Weill Cornell Medical College, New York Presbyterian Hospital  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.5.370"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.05.005"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.58"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00295569"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00278704"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2006.043059"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1076\/opge.22.1.11.2235"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1996"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26138"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100140521001"},{"key":"e_1_2_9_12_1","first-page":"1499","article-title":"Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation","volume":"2","author":"Chan HSL","year":"1996","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044322"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301450"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.0244"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.12.014"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.05.007"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197081"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yaoo.2017.03.008"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000266"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.12.015"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.5"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034120"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108692"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.01.026"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.03.028"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084247"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.11.029"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22354"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-620X.192278"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210647"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308591"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-013-9416-8"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-017-0093-8"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.28845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.28845","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.28845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T19:58:06Z","timestamp":1692734286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.28845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/pbc.28845"],"URL":"https:\/\/doi.org\/10.1002\/pbc.28845","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"assertion":[{"value":"2020-12-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e28845"}}